3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Classical hematology
1
Conditions
Prostatic Neoplasms
47
Breast Neoplasms
34
Breast Neoplasms, Male
3
Neoplasms
2
Neoplasm Metastasis
2
Infertility
2
Advanced Breast Cancer
2
Sexual Dysfunction, Physiological
1
Recurrence
1
Prostate Adenocarcinoma
1
Primary Ovarian Insufficiency
1
Osteoporosis
1
Osteitis Deformans
1
Leiomyoma
1
Hot Flashes
1
Hemorrhage
1
Breast Cancer Invasive
1
Anemia
1
Advanced Prostate Cancer
1
Advanced Metastatic Breast Cancer
1
Interventions
Epoetin Alfa
27
Darbepoetin alfa
13
epoetin beta
3
Erythropoietin
3
telapristone acetate
2
luspatercept
2
ferric carboxymaltose
2
Lenalidomide
2
Ferric Oxide, Saccharated
2
Cisplatin
2
Blood Transfusion
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
ibrutinib
1
fludarabine phosphate
1
fludarabine
1
ferrous sulfate
1
ferric gluconate
1
ferric derisomaltose
1
fanasil, pyrimethamine drug combination
1
Taxes
1
Sugars
1
Sucrose
1
Solutions
1
Saline Solution
1
Rituximab
1
Radiotherapy
1
Pharmacogenomic Testing
1
Paclitaxel
1
Iron-Dextran Complex
1
Injections
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Anemia
×
Goserelin
×
Clear all
NCT00303784
2020-11-27
PATCH
University College, London
Phase 3
Unknown
2,200 enrolled